Friday, 17 Nov 2017

You are here

lxekizumab Performance in TNF Nonresponders Phase 3 Trial

Ixekizumab performs well in TNF nonresponders phase 3 trial.

With more IL17 inhibitors becoming available for treatment of seronegative spondyloarthropathies the question of efficacy and safety in different clinical scenarios arises.

The phase 3 PsA SPIRIT-P2 trial involving 363 patients with PsA who failed or could not tolerate 1-2 TNFi randomized patients into 3 groups: PBO, IXE 80 mg q 2 weeks and IXE 80 mg q 4 weeks.

Acr 20 was assessed in 24 weeks as a primary end point. 16 week escape was allowed.

 

 

Best response was observed in arthritis and dactylitis domain in both IXE groups with ACR20 65 [53.3%], 59 [48%] vs. 23 [19.5%]; Q4W, Q2W, placebo, respectively. At the same, rates of enthesitis resolution were not significantly different compared to placebo. 

 

In terms of safety, serious AE and oral candidiasis were numerically higher with Q2W vs placebo. No deaths or cases of inflammatory bowel disease, uveitis, TB reactivation, or grade ≥3 neutropenia were reported.

The study concluded that IXE improves arthritis, skin psoriasis and physical function with no unexpected safety findings in patients with active PsA and prior IR or intolerance to TNF-inhibitor(s).

The safety profile of IXE was comparable to safety findings from SPIRIT-P1 trial.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 17 November 2017

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

Podcast of ACR17 - Day 4

Care to learn what you missed at last weeks ACR 2017 meeting in San Diego?  Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers.  Another good way to learn from RheumNow.

The ACR17 RheumNow Week in Review - 10 November 2017

This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr. Jack Cush reviews lupus and the microbiome, daily podcasts, pregnancy and lactation, osteoporosis drug holidays and screening for pulmonary hypertension.

Many thanks to the RheumNow Faculty for their work and expertise!

Podcast of ACR 17 - Day 3

Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !

ACR 2017 - Day 3 and 4 Highlights

Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report).  Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.